liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Effects of AZD0837, a Novel Direct Thrombin Inhibitor, on the Electrophysiological Properties of the Human Heart A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study
Linköping University, Department of Medicine and Health Sciences, Cardiology . Linköping University, Faculty of Health Sciences. Östergötlands Läns Landsting, Heart Centre, Department of Cardiology.ORCID iD: 0000-0003-3059-4404
Sahlgrenska University Hospital.
Örebro University Hospital.
Karolinska University Hospital.
Show others and affiliations
2010 (English)In: Clinical drug investigation, ISSN 1173-2563, Vol. 30, no 7, 461-471 p.Article in journal (Refereed) Published
Abstract [en]

Background AZD0837 is an investigational oral anticoagulant that is bioconverted to its active form, AR-H067637, a selective direct thrombin inhibitor.

 Objectives The objectives of the present study were to investigate if there are any clinically relevant adverse effects of intravenous AZD0837 on cardiac conduction, refractoriness and repolarization, and to study its safety and tolerability.

 Methods In this randomized, double-blind, parallel-group, placebo-controlled study (study code D1250C00026), invasive electrophysiological measurements were performed twice in 30 subjects with a history of, or ongoing, atrial flutter, starting 30 minutes after successful ablation of atrial flutter and then 60 minutes after start of an intravenous infusion of AZD0837. Pre-study warfarin therapy was not an exclusion criterion. The stimulation protocol was performed mainly at 500 and 400 ms drive cycle length. A 12-lead ECG was also recorded before and during AZD0837 infusion. Plasma concentrations of AZD0837 and its metabolites were obtained at predefined timepoints.

 Results Measurements were made at baseline and during stable plasma concentrations of the prodrug AZD0837 (mean ± standard deviation 7.96 ± 2.38 μmol/L, approximate target of 10 μmol/L), the intermediate metabolite AR-H69927 (1.26 ± 0.39 μmol/L, target 1-2 μmol/L) and the active direct thrombin inhibitor AR-H067637 (0.35 ± 0.14 μmol/L, target 0.5-1.0 μmol/L). There were no clinically relevant effects on cardiac conduction (QRS duration, PR interval, His bundle electrogram, Wenckebach point), refractoriness (atrial, atrioventricular and ventricular effective refractory periods) or repolarization (QT, QT interval corrected for heart rate using Fridericia's formula, QRS onset to the top of the T wave [QTtop], QRS onset to the end of the T wave [QTend] or QTtop - QTend). 

Conclusions AZD0837 was well tolerated, and had no clinically relevant effects on cardiac electrophysiology of the target population, either in subjects previously treated with warfarin or in those without previous treatment. 

Place, publisher, year, edition, pages
Adis International Limited , 2010. Vol. 30, no 7, 461-471 p.
Keyword [en]
Anticoagulants, pharmacodynamics; Atrial-flutter; AZD-0837, pharmacodynamics; Research-and-development; Thrombin-inhibitors, therapeutic use
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-58273DOI: 10.2165/11536300-000000000-00000ISI: 000279296600004PubMedID: 20528001OAI: diva2:337936
Available from: 2010-08-10 Created: 2010-08-09 Last updated: 2013-12-17

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Walfridsson, Håkan
By organisation
Cardiology Faculty of Health SciencesDepartment of Cardiology
In the same journal
Clinical drug investigation
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 37 hits
ReferencesLink to record
Permanent link

Direct link